Victory Capital Management
RPRX icon

Victory Capital Management’s Royalty Pharma RPRX Stock Holding History

Victory Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207M Sell
3,682,932
-170,876
-4% -$8.89M 0.12% 198
2026
Q1 		$185M Sell
3,853,808
-1,253,097
-25% -$54.9M 0.12% 206
2025
Q4 		$197M Buy
5,106,905
+449,498
+10% +$17.1M 0.11% 182
2025
Q3 		$164M Buy
4,657,407
+165,727
+4% +$6M 0.1% 203
2025
Q2 		$162M Buy
4,491,680
+868,546
+24% +$28.8M 0.1% 210
2025
Q1 		$113M Buy
3,623,134
+2,644,923
+270% +$83.8M 0.12% 199
2024
Q4 		$25M Buy
978,211
+129,176
+15% +$3.43M 0.02% 759
2024
Q3 		$24M Buy
849,035
+179,411
+27% +$4.97M 0.02% 784
2024
Q2 		$17.7M Buy
669,624
+211,131
+46% +$5.85M 0.02% 851
2024
Q1 		$13.9M Buy
458,493
+192,782
+73% +$5.68M 0.01% 943
2023
Q4 		$7.46M Sell
265,711
-73,179
-22% -$2.01M 0.01% 1151
2023
Q3 		$9.2M Buy
338,890
+28,851
+9% +$857K 0.01% 1048
2023
Q2 		$9.53M Buy
310,039
+23,960
+8% +$812K 0.01% 1062
2023
Q1 		$10.3M Buy
286,079
+17,535
+7% +$650K 0.01% 1019
2022
Q4 		$10.6M Buy
268,544
+9,221
+4% +$385K 0.01% 1003
2022
Q3 		$10.4M Buy
259,323
+102,847
+66% +$4.39M 0.01% 1054
2022
Q2 		$6.58M Sell
156,476
-13,367
-8% -$548K 0.01% 1186
2022
Q1 		$7.23M Buy
169,843
+135,102
+389% +$5.31M 0.01% 1214
2021
Q4 		$1.38M Sell
34,741
-55,183
-61% -$2.14M ﹤0.01% 1685
2021
Q3 		$3.25M Sell
89,924
-1,164,574
-93% -$45.3M ﹤0.01% 1448
2021
Q2 		$51.4M Sell
1,254,498
-1,933,796
-61% -$82.3M 0.05% 555
2021
Q1 		$139M Sell
3,188,294
-519,438
-14% -$24.6M 0.14% 175
2020
Q4 		$186M Buy
3,707,732
+866,849
+31% +$36.8M 0.21% 104
2020
Q3 		$120M Sell
2,840,883
-410,227
-13% -$17.6M 0.15% 172
2020
Q2 		$158M Buy
+3,251,110
New +$161M 0.21% 107

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management's RPRX Position: Q2 2026 in Review

Victory Capital Management reduced its Royalty Pharma (RPRX) stake by 4.4% in Q2 2026, selling an estimated $8.89M and leaving 3,682,932 shares worth $207M. The position accounts for 0.12% of the portfolio, ranked #198.

Victory Capital Management first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Victory Capital Management held 3,682,932 shares of Royalty Pharma worth $207M as of Q2 2026.
  • Victory Capital Management sold 170,876 Royalty Pharma shares in Q2 2026, an estimated $8.89M.
  • Royalty Pharma made up 0.12% of Victory Capital Management's portfolio in Q2 2026, its #198 holding.
  • Victory Capital Management first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.